Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant

Abstract Background Cognitive dysfunction is part of the broad spectrum of clinical manifestations in older untreated hereditary transthyretin amyloidosis patients with peripheral polyneuropathy. Objective The objective of this study is to systematically explore cognitive dysfunction in ATTRV30M amyloidosis patients whose disease course was modified by liver transplant (LT). Methods A series of 269 carriers of TTRVal30Met mutation treated with LT underwent a neuropsychological assessment. Clinical charts were reviewed to identify focal neurological episodes (FNEs), cognitive complaints and laboratory results. Chi-square and Mann–Whitney tests explored potential predictors of cognitive dysfunction. Results Cognitive dysfunction was identified in 35 patients (13%)−14 (5%) had mild and 21 (8%) had moderate dysfunction. In comparison to normal cognition, both mild and moderate cognitive dysfunction patients had older age, higher mPND score and elevated NT-proBNP and Cystatin C values. Mild cognitive dysfunction was associated with longer disease duration and history of FNEs, whereas moderate dysfunction was related to older age at disease onset and more cognitive complaints and depression symptoms. Conclusions Consistent with the natural history of the disease, older age and higher severity of the disease are significantly associated and potentially predictors of cognitive dysfunction in ATTRV30M patients treated with LT. The level of cognitive dysfunction may depend on some clinical variables.

[1]  T. Iwaki,et al.  Concurrent cardiac transthyretin and brain β amyloid accumulation among the older adults: The Hisayama study , 2021, Brain pathology.

[2]  A. Çakar,et al.  An Exploratory Study of Cognitive Involvement in Hereditary Transthyretin Amyloidosis , 2021, Acta neurologica Scandinavica.

[3]  M. Benson,et al.  Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines , 2020, Therapeutics and clinical risk management.

[4]  P. Hawkins,et al.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy , 2020, Journal of Neurology.

[5]  E. Dardiotis,et al.  The frequency of central nervous system complications in the Cypriot cohort of ATTRV30M neuropathy transplanted patients , 2020, Neurological Sciences.

[6]  Y. Ando,et al.  Comparison of clinical features in transient focal neurological episodes between hereditary transthyretin type and Aβ type cerebral amyloid angiopathy , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[7]  O. Suhr,et al.  Atrial Fibrillation and Central Nervous Complications in Liver Transplanted Hereditary Transthyretin Amyloidosis Patients , 2017, Transplantation.

[8]  J. Kelly,et al.  Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis , 2018, Journal of Neurology.

[9]  I. Martins,et al.  Cognitive impairment in liver transplanted patients with transthyretin-related hereditary amyloid polyneuropathy , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[10]  M. Carvalho,et al.  Epileptic seizures as a presentation of central nervous system involvement in TTR Val30Met-FAP , 2016, Journal of Neurology.

[11]  F. Kametani,et al.  Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis , 2016, Neurology.

[12]  M. Mascalchi,et al.  Brain Microbleeds 12 Years after Orthotopic Liver Transplantation in Val30Met Amyloidosis. , 2015, Journal of Stroke & Cerebrovascular Diseases.

[13]  Y. Sekijima Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  T. Coelho,et al.  CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  Teresa Coelho,et al.  Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  Xinyi Li,et al.  Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease? , 2011, Molecular Neurodegeneration.

[17]  T. Hirai,et al.  Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis , 2005, Neurology.

[18]  Y. Ando,et al.  Impact of age and amyloidosis on thiol conjugation of transthyretin in hereditary transthyretin amyloidosis. , 1999, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[19]  C ANDRADE,et al.  A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. , 1952, Brain : a journal of neurology.